Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials

Table 2

Overview of included studies and patient characteristics ().

No.	Study	Study design	Sponsor	Country	Sample size	Follow-up (months)	Interventions	Male (%)	Mean age (SD)	CAD (%)	PAD (%)	History of stroke/CV disease (%)
1	CAPRIE [19]	Multicentre, double blind	Sanofi and Bristol-MyersSquibb	International (Australia, Austria, Belgium, Canada, Finland, France, Germany, Italy, Netherlands, New Zealand, Portugal, Spain, Sweden, Switzerland, UK, USA)	19,185	Mean: 22.9	Clopidogrel 75 mg od	(72)	62.5 (11.1)	–	–	[9]
							ASA 325 mg od	(72)	62.5 (11.1)	–	–	[9]
2	CHARISMA, NCT00050817 [1]	Multicentre, double blind, phase III study	Sanofi-Aventis and Bristol-Myers Squibb	International (Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, UK, USA)	15,603	Median: 28	Clopidogrel 75 mg od+ASA 75-162 mg od	5,486 (70.3)	–	2,892 (47.70)	1,760 (22.60)	2,157 (35.60)
							ASA 75-162 mg od	5,473 (70.2)	–	2,943 (48.30)	1,771 (22.70)	2,163 (35.50)
3	COMPASS, NCT01776424 [15]	Multicentre, double blind, phase III study	Bayer	International (Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Ecuador, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Malaysia, Netherlands, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Sweden, Switzerland, Ukraine, UK, USA)	27,395	Mean: 23	Rivaroxaban 5 mg bid	7,145 (78.4)	68.2 (7.9)	8,250 (90.50)	2,474 (27.10)	346 (3.80)
							Rivaroxaban 2.5 mg bid+ASA 100 mg od	7,093 (77.5)	68.3 (7.9)	8,313 (90.80)	2,492 (27.20)	351 (3.80)
							ASA 100 mg od	7,137 (78.2)	68.2 (8.0)	8,261 (90.50)	2,504 (27.40)	335 (3.70)
4	TRA 2°P–TIMI 50, NCT00526474 [20]	Multicentre, double blind, phase III study	Merck	International (Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, Switzerland, UK, USA)	26,449	Median: 30	Vorapaxar 2.5 mg od	10,071 (76.2)	–	8,898 (67.3)	2,901 (21.9)	3,139 (23.70)
							Placebo	10,052 (76.0)	–	8,881 (67.2)	2,944 (22.3)	3,129 (23.70)

ASA: acetylsalicylic acid; bid: bis in die = twice a day; CAD: coronary artery disease; CV: cardiovascular; od: once a day; PAD: peripheral artery disease.